Patients using Mepolizumab experienced significant improvement in nasal polyps, nasal obstruction, smell and overall symptoms
MILWAUKEE, Feb. 19, 2025 /PRNewswire-PRWeb/ -- Mepolizumab significantly improved changes in nasal polyps (NP) for patients with chronic rhinosinusitis with nasal polyps compared to a placebo, according to new research being presented at the 2025 AAAAI / WAO Joint Congress in San Diego, CA, later this month.
In Phase III of the SYNAPSE trial researchers found that mepolizumab significantly reduces the risk of repeat sinus surgery in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). During the study, researchers compared the impact of mepolizumab in patients with prior nasal polyp (NP) surgery, randomizing patients 1:1 to receive 100mg of subcutaneous mepolizumab along with standard care. At week 52 of the study, key patient-reported outcomes and clinical endpoints were assessed after treatment.
In the research, 189 participants had one prior surgery, with 108 receiving mepolizumab and 81 receiving a placebo, and 218 participants had more than one prior surgery with 98 receiving mepolizumab and 120 receiving a placebo. In both prior surgery subgroups, mepolizumab significantly improved changes in nasal polyps (NP) compared to a placebo, as well as making significant improvements in a nasal obstruction visual analog scale (VAS) score, smell, overall symptoms and Sino-Nasal Outcome test compared to the placebo.
Researchers found that mepolizumab reduced the time to first surgery by 73% in the subgroup with one prior surgery and 39% in the subgroup with more than one surgery versus the placebo. Additionally, the study found a 63% reduction in the odds of requiring oral corticosteroid (OCS) course in the subgroup with one prior surgery and 6% in the subgroup of more than one prior surgery.
Mepolizumab significantly improves outcomes in patients with CRSwNP with one or more prior NP surgeries, with more pronounced benefits in surgery risk and OCS use in patients with one prior surgery.
Visit aaaai.org to learn more about chronic rhinosinusitis with nasal polyps. Research presented at the 2025 AAAAI / WAO Joint Congress, February 28 – March 3 in San Diego, CA, is published in an online supplement to The Journal of Allergy and Clinical Immunology (JACI).
The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading membership organization of more than 7,100 allergists, asthma specialists, clinical immunologists and other professionals with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI is the go-to resource for patients living with allergies, asthma and immune deficiency disorders.
Media Contact
Candace Archie, The American Academy of Allergy, Asthma & Immunology, (414) 272-6071, [email protected], aaaai.org
SOURCE The American Academy of Allergy, Asthma & Immunology
Share this article